ALICIA SHELLY: Open Payments
NPI 1992022719 · DOUGLASVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$85,843 in 193 payments from 11 companies in 2025. Trend: 2023 $12,265 · 2024 $102,193 · 2025 $85,843
Speaker / faculty: $76,475Travel & lodging: $7,882Food & beverage: $1,486
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 161 | $85,097 |
| Novo Nordisk Inc | 15 | $321 |
| VIVUS LLC | 1 | $120 |
| Abbott Laboratories | 5 | $93 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $71 |
| Amgen Inc. | 2 | $33 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $29 |
| ABBVIE INC. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
Products named: ZEPBOUND, MOUNJARO, QSYMIA, Wegovy, FREESTYLE LIBRE 3, Ozempic, Rybelsus, EVENITY.
Industry payments across GA — which companies pay providers there.
